Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?
Saki Takahashi, Bryan Greenhouse, Isabel Rodríguez-Barraquer
Abstract
Biased seroprevalence estimates can occur using serological assays optimized with validation sets unrepresentative of disease spectrum in the general population. Correct interpretation of serosurveys for severe acute respiratory syndrome coronavirus 2 requires quantifying variations in sensitivity with disease severity and over time.
Topics & Concepts
SeroprevalenceMedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusSerology2019-20 coronavirus outbreakPopulationDiseaseRespiratory systemVirologyInternal medicineImmunologyInfectious disease (medical specialty)AntibodyEnvironmental healthOutbreakSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies